Dave I agree with you 100% and trust your son has stronger science background than most here including myself. There is no use arguing over it or even trying to make people understand who are not interested in doing so. Especially since like you acknowledge MANF diabetes etc is still years away. Right now its really about continuing positive data in RP which strengthens the ocular platform (our first target). Obviously our biggest concerns for both near term value as well as near term funding/dilution truly regards MSPrecise/Lympro/Eltoprazine.